Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation

Dong Geun Sul, Hyo Shin Kim, Dongho Lee, Seong Soo Joo, Kwang Woo Hwang, So Young Park

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Aims: The progressive accumulation of beta-amyloid peptide (Aβ), in the form of senile plaques, has been recognized as one of the major causes of Alzheimer's disease (AD) pathology. Increased production of Aβ and the aggregation of Aβ to oligomers have been reported to trigger neurotoxicity, oxidative damage and inflammation. Furthermore, Aβ-induced tau hyperphosphorylation and neurotoxicity are downstream of Aβ. Therefore, we studied the possible neuroprotective effects of caffeic acid against Aβ-induced toxicity. Main methods: Treatment of PC12 cells with 10 μM Aβ (25-35) for 24 h significantly decreased the cell viability; this was accompanied by an increase in intracellular calcium levels and tau phosphorylation with GSK-3β (glycogen synthase kinase-3β) activation (phosphorylation). Key findings: However, pretreatment of the PC12 cells with 10 and 20 μg/ml of caffeic acid, for 1 h prior to Aβ, significantly reversed the Aβ-induced neurotoxicity by attenuating the elevation of intracellular calcium levels and tau phosphorylation. Significance: Taken together, these results suggest that caffeic acid protected the PC12 cells against Aβ-induced toxicity. In addition, the neuroprotective mechanisms of caffeic acid against Aβ attenuated intracellular calcium influx and decreased tau phosphorylation by the reduction of GSK-3β activation.

Original languageEnglish
Pages (from-to)257-262
Number of pages6
JournalLife Sciences
Volume84
Issue number9-10
DOIs
Publication statusPublished - 2009 Feb 27

Fingerprint

Phosphorylation
Amyloid
PC12 Cells
Calcium
Glycogen Synthase Kinase 3
Toxicity
Chemical activation
Amyloid Plaques
Neuroprotective Agents
Pathology
Oligomers
Cell Survival
Alzheimer Disease
Agglomeration
Cells
Inflammation
caffeic acid
Inhibition (Psychology)

Keywords

  • Antioxidant
  • Beta-amyloid
  • Caffeic acid
  • Calcium influx
  • GSK-3β
  • Tau phosphorylation

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. / Sul, Dong Geun; Kim, Hyo Shin; Lee, Dongho; Joo, Seong Soo; Hwang, Kwang Woo; Park, So Young.

In: Life Sciences, Vol. 84, No. 9-10, 27.02.2009, p. 257-262.

Research output: Contribution to journalArticle

Sul, Dong Geun ; Kim, Hyo Shin ; Lee, Dongho ; Joo, Seong Soo ; Hwang, Kwang Woo ; Park, So Young. / Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. In: Life Sciences. 2009 ; Vol. 84, No. 9-10. pp. 257-262.
@article{b40ff962556245789bbecee8d12b1d39,
title = "Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation",
abstract = "Aims: The progressive accumulation of beta-amyloid peptide (Aβ), in the form of senile plaques, has been recognized as one of the major causes of Alzheimer's disease (AD) pathology. Increased production of Aβ and the aggregation of Aβ to oligomers have been reported to trigger neurotoxicity, oxidative damage and inflammation. Furthermore, Aβ-induced tau hyperphosphorylation and neurotoxicity are downstream of Aβ. Therefore, we studied the possible neuroprotective effects of caffeic acid against Aβ-induced toxicity. Main methods: Treatment of PC12 cells with 10 μM Aβ (25-35) for 24 h significantly decreased the cell viability; this was accompanied by an increase in intracellular calcium levels and tau phosphorylation with GSK-3β (glycogen synthase kinase-3β) activation (phosphorylation). Key findings: However, pretreatment of the PC12 cells with 10 and 20 μg/ml of caffeic acid, for 1 h prior to Aβ, significantly reversed the Aβ-induced neurotoxicity by attenuating the elevation of intracellular calcium levels and tau phosphorylation. Significance: Taken together, these results suggest that caffeic acid protected the PC12 cells against Aβ-induced toxicity. In addition, the neuroprotective mechanisms of caffeic acid against Aβ attenuated intracellular calcium influx and decreased tau phosphorylation by the reduction of GSK-3β activation.",
keywords = "Antioxidant, Beta-amyloid, Caffeic acid, Calcium influx, GSK-3β, Tau phosphorylation",
author = "Sul, {Dong Geun} and Kim, {Hyo Shin} and Dongho Lee and Joo, {Seong Soo} and Hwang, {Kwang Woo} and Park, {So Young}",
year = "2009",
month = "2",
day = "27",
doi = "10.1016/j.lfs.2008.12.001",
language = "English",
volume = "84",
pages = "257--262",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "9-10",

}

TY - JOUR

T1 - Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation

AU - Sul, Dong Geun

AU - Kim, Hyo Shin

AU - Lee, Dongho

AU - Joo, Seong Soo

AU - Hwang, Kwang Woo

AU - Park, So Young

PY - 2009/2/27

Y1 - 2009/2/27

N2 - Aims: The progressive accumulation of beta-amyloid peptide (Aβ), in the form of senile plaques, has been recognized as one of the major causes of Alzheimer's disease (AD) pathology. Increased production of Aβ and the aggregation of Aβ to oligomers have been reported to trigger neurotoxicity, oxidative damage and inflammation. Furthermore, Aβ-induced tau hyperphosphorylation and neurotoxicity are downstream of Aβ. Therefore, we studied the possible neuroprotective effects of caffeic acid against Aβ-induced toxicity. Main methods: Treatment of PC12 cells with 10 μM Aβ (25-35) for 24 h significantly decreased the cell viability; this was accompanied by an increase in intracellular calcium levels and tau phosphorylation with GSK-3β (glycogen synthase kinase-3β) activation (phosphorylation). Key findings: However, pretreatment of the PC12 cells with 10 and 20 μg/ml of caffeic acid, for 1 h prior to Aβ, significantly reversed the Aβ-induced neurotoxicity by attenuating the elevation of intracellular calcium levels and tau phosphorylation. Significance: Taken together, these results suggest that caffeic acid protected the PC12 cells against Aβ-induced toxicity. In addition, the neuroprotective mechanisms of caffeic acid against Aβ attenuated intracellular calcium influx and decreased tau phosphorylation by the reduction of GSK-3β activation.

AB - Aims: The progressive accumulation of beta-amyloid peptide (Aβ), in the form of senile plaques, has been recognized as one of the major causes of Alzheimer's disease (AD) pathology. Increased production of Aβ and the aggregation of Aβ to oligomers have been reported to trigger neurotoxicity, oxidative damage and inflammation. Furthermore, Aβ-induced tau hyperphosphorylation and neurotoxicity are downstream of Aβ. Therefore, we studied the possible neuroprotective effects of caffeic acid against Aβ-induced toxicity. Main methods: Treatment of PC12 cells with 10 μM Aβ (25-35) for 24 h significantly decreased the cell viability; this was accompanied by an increase in intracellular calcium levels and tau phosphorylation with GSK-3β (glycogen synthase kinase-3β) activation (phosphorylation). Key findings: However, pretreatment of the PC12 cells with 10 and 20 μg/ml of caffeic acid, for 1 h prior to Aβ, significantly reversed the Aβ-induced neurotoxicity by attenuating the elevation of intracellular calcium levels and tau phosphorylation. Significance: Taken together, these results suggest that caffeic acid protected the PC12 cells against Aβ-induced toxicity. In addition, the neuroprotective mechanisms of caffeic acid against Aβ attenuated intracellular calcium influx and decreased tau phosphorylation by the reduction of GSK-3β activation.

KW - Antioxidant

KW - Beta-amyloid

KW - Caffeic acid

KW - Calcium influx

KW - GSK-3β

KW - Tau phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=59649111139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649111139&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2008.12.001

DO - 10.1016/j.lfs.2008.12.001

M3 - Article

C2 - 19101570

AN - SCOPUS:59649111139

VL - 84

SP - 257

EP - 262

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 9-10

ER -